Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Monitoring & Adjustments Regular check-ins track progress and side effects, with doctors adjusting doses as needed
Consistent dosing matters more than injection temperature
PMID: 35413689
In May 2022, Tirzepatide was approved for marketing by the FDA for the treatment of type 2 diabetes in adults
Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, et al
Requirements usually include: (1) BMI 30 , or BMI 27 with at least one weight-related health condition (type 2 diabetes, high blood pressure, or high cholesterol per FDA labeling), (2) participation in a 6-month weight management program (diet, exercise, and lifestyle changes), (3) chart notes documenting BMI and health conditions, and (4) no contraindications such as personal/family history of medullary thyroid cancer or MEN2 syndrome (a rare genetic condition)
